Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness

Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness

Background: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. Objectives: The main objectives of the study were to establish the clinical effect...

Full description

Bibliographic Details
Main Authors: Thomas RE Barnes, Verity C Leeson, Carol Paton, Louise Marston, Linda Davies, William Whittaker, David Osborn, Raj Kumar, Patrick Keown, Rameez Zafar, Khalid Iqbal, Vineet Singh, Pavel Fridrich, Zachary Fitzgerald, Hemant Bagalkote, Peter M Haddad, Mariwan Husni, Tim Amos
Format: Article
Language:English
Published: NIHR Journals Library 2017-09-01
Series:Health Technology Assessment
Subjects:
amisulpride
clozapine
schizophrenia
treatment-resistant schizophrenia
randomised controlled trial
placebo controlled
cost-effectiveness
Online Access:https://doi.org/10.3310/hta21490

Internet

https://doi.org/10.3310/hta21490

Similar Items